VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 29, 2007) - Inflazyme Pharmaceuticals Ltd. (TSX: IZP), today announced that it has been advised that Orexo AB (OMX Nordic List, Mid Cap:ORX) ("Orexo") has postponed its Extraordinary General Meeting until November 13, 2007. The meeting, originally set for November 1, 2007, is to seek shareholder approval of the acquisition of Biolipox AB ("Biolipox") by Orexo. As previously announced, we were advised that the new entity will retain the name Orexo, and the President and CEO of Biolipox, Dr. Torbjorn Bjerke will serve as the President and CEO of the new entity.
